` XFOR (X4 Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

XFOR
vs
S&P 500

Over the past 12 months, XFOR has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's 9% growth.

Stocks Performance
XFOR vs S&P 500

Loading
XFOR
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
XFOR vs S&P 500

Loading
XFOR
S&P 500
Difference
www.alphaspread.com

Performance By Year
XFOR vs S&P 500

Loading
XFOR
S&P 500
Add Stock

Competitors Performance
X4 Pharmaceuticals Inc vs Peers

S&P 500
XFOR
ABBV
AMGN
GILD
VRTX
Add Stock

X4 Pharmaceuticals Inc
Glance View

Market Cap
15.7m USD
Industry
Biotechnology

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company is headquartered in Boston, Massachusetts and currently employs 83 full-time employees. The company went IPO on 2017-11-16. The firm is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

XFOR Intrinsic Value
Not Available
Back to Top